Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Cogent Biosciences stock
Learn how to easily invest in Cogent Biosciences stock.
Cogent Biosciences Inc is a biotechnology business based in the US. Cogent Biosciences shares (COGT) are listed on the NASDAQ and all prices are listed in US Dollars. Cogent Biosciences employs 15 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Cogent Biosciences
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – COGT – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Cogent Biosciences stock price (NASDAQ: COGT)Use our graph to track the performance of COGT stocks over time.
Cogent Biosciences shares at a glance
|Latest market close||$6.79|
|52-week range||$5.83 - $11.76|
|50-day moving average||$8.65|
|200-day moving average||$8.25|
|Wall St. target price||$22.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-4.93|
Buy Cogent Biosciences shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Cogent Biosciences stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Cogent Biosciences price performance over time
|1 week (2022-01-21)||-11.24%|
|1 month (2021-12-24)||N/A|
|3 months (2021-10-28)||-20.86%|
|6 months (2021-07-28)||7.61%|
|1 year (2021-01-28)||-25.30%|
|2 years (2020-01-28)||614.89%|
|3 years (2019-01-28)||79.16%|
|5 years (2017-01-24)||N/A|
Cogent Biosciences financials
|Gross profit TTM||$-15,967,000|
|Return on assets TTM||-20.12%|
|Return on equity TTM||-37.47%|
|Market capitalisation||$301.7 million|
TTM: trailing 12 months
Cogent Biosciences share dividends
We're not expecting Cogent Biosciences to pay a dividend over the next 12 months.
Have Cogent Biosciences's shares ever split?
Cogent Biosciences's shares were split on a 1:4 basis on 8 November 2020. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cogent Biosciences shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Cogent Biosciences shares which in turn could have impacted Cogent Biosciences's share price.
Cogent Biosciences overview
Cogent Biosciences, Inc. , a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. Cogent Biosciences, Inc. has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of CGT9486 and CGT0206 inhibitors. The company was formerly known as Unum Therapeutics Inc.
Cogent Biosciences in the news
Ackman takes a big stake in Netflix, excited about company's long-term prospects
What to watch today: Stock futures turn positive, reversing big overnight losses
5 things to know before the stock market opens Thursday
Frequently asked questionsWhat percentage of Cogent Biosciences is owned by insiders or institutions?
Currently 0.011% of Cogent Biosciences shares are held by insiders and 106.039% by institutions. How many people work for Cogent Biosciences?
Latest data suggests 15 work at Cogent Biosciences. When does the fiscal year end for Cogent Biosciences?
Cogent Biosciences's fiscal year ends in December. Where is Cogent Biosciences based?
Cogent Biosciences's address is: 200 Cambridge Park Drive, Cambridge, MA, United States, 02140 What is Cogent Biosciences's ISIN number?
Cogent Biosciences's international securities identification number is: US19240Q2012
More guides on Finder
Cathie Wood’s ARK analysts predict Bitcoin at $1 million each by 2030
Five major factors contribute to the continued bull run of Bitcoin, ARK says, including growing adoption and long-term focus of investors.
Lido’s liquid staking allows investors holding LUNA and less than 32 ETH to reap the rewards of DeFi staking.
Stocks are dropping; 3 rules for buying on the dip
Downturns often let you buy fundamentally strong stocks at bargain prices, but mind the fundamentals and consider these 3 rules.
The crypto market has lost $1.5 trillion in value — time to buy?
The crypto market wiped out $1.5 trillion in value in just three months.
Bitcoin tumbles past $40,000, altcoins follow
Bitcoin breached the $40,000 price level and may plummet lower as Russia signals a potential ban.
Cardano’s Pavia plot sale shows land rush is on in the metaverse
Cardano’s first metaverse project is available to investors now — if you can find a piece of digital land on sale. Plots sold fast despite the project’s early stage limitations.
Walmart dives deep into the metaverse with crypto and NFTs
Walmart files trademarks with the goal to issue its own cryptocurrency and NFTs for use in its digital stores.
Melania Trump has an NFT — what to know before you buy
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Vigorus (VIS) price prediction
Read our expert analysis on Vigorus and how the token will perform in the future.
Dogecoin jumps 10% on word you can use it to buy Tesla merch
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
Ask an Expert